WHO Leak: Gilead's Remdesivir has no Clinical Benefit

Yesterday, the WHO's website leaked a draft on remdesivir, casting doubt on its effectiveness referring to a Chinese clinical trial. Gilead (GILD) fell hard yesterday as a result. Lately, remdesivir has casted several doubts. "Results based on anecdotal evidence" and studies without control groups.

It seems that betting on 'potential' treatments against the virus is pretty risky since not all results have been transparent enough.